Foursixthree Capital LP Arbutus Biopharma Corp Transaction History
Foursixthree Capital LP
- $363 Billion
- Q1 2025
A detailed history of Foursixthree Capital LP transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Foursixthree Capital LP holds 2,450,421 shares of ABUS stock, worth $7.69 Million. This represents 2.36% of its overall portfolio holdings.
Number of Shares
2,450,421Holding current value
$7.69 Million% of portfolio
2.36%Shares
1 transactions
Others Institutions Holding ABUS
# of Institutions
189Shares Held
111MCall Options Held
866KPut Options Held
608K-
Morgan Stanley New York, NY23.8MShares$74.7 Million0.01% of portfolio
-
Whitefort Capital Management, LP New York, NY13.3MShares$41.8 Million27.3% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$36.3 Million0.0% of portfolio
-
Two Seas Capital LP Rye, NY9.47MShares$29.7 Million1.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.95MShares$28.1 Million0.0% of portfolio
About Arbutus Biopharma Corp
- Ticker ABUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 149,951,008
- Market Cap $471M
- Description
- Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...